Walgreens Boots Alliance, Inc. (WBA) Income Statement Analysis

See more : Alice Consolidated Mines, Inc. (ACNE) Income Statement Analysis – Financial Results

Complete financial analysis of Walgreens Boots Alliance, Inc. (WBA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Walgreens Boots Alliance, Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.

You may be interested

Alrov Properties and Lodgings Ltd. (ALRPR.TA) Income Statement Analysis – Financial Results
The Sukhjit Starch & Chemicals Limited (SUKHJITS.BO) Income Statement Analysis – Financial Results
China Beidahuang Industry Group Holdings Limited (0039.HK) Income Statement Analysis – Financial Results
Sociedad de Inversiones Oro Blanco S.A. (ORO-BLANCO.SN) Income Statement Analysis – Financial Results
Orphazyme A/S (ORPHY) Income Statement Analysis – Financial Results

Walgreens Boots Alliance, Inc. (WBA)

Industry: Medical - Pharmaceuticals

Sector: Healthcare

Website: https://www.walgreensbootsalliance.com

About Walgreens Boots Alliance, Inc.

Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and beauty retail company. It operates through two segments, the United States and International. The United States segment sells prescription drugs and an assortment of retail products, including health, wellness, beauty, personal care, consumable, and general merchandise products through its retail drugstores. It also provides central specialty pharmacy services and mail services. As of August 31, 2021, this segment operated 8,965 retail stores under the Walgreens and Duane Reade brands in the United States; and five specialty pharmacies. The International segment sells prescription drugs; and health and wellness, beauty, personal care, and other consumer products through its pharmacy-led health and beauty retail stores and optical practices, as well as through boots.com and an integrated mobile application. It also engages in pharmaceutical wholesaling and distribution business in Germany. As of August 31, 2021, this segment operated 4,031 retail stores under the Boots, Benavides, and Ahumada in the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile; and 548 optical practices, including 160 on a franchise basis. Walgreens Boots Alliance, Inc. was founded in 1901 and is based in Deerfield, Illinois.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985
Revenue	147.66B	139.08B	132.70B	132.51B	121.98B	120.07B	131.54B	118.21B	117.35B	103.44B	76.39B	72.22B	71.63B	72.18B	67.42B	63.34B	59.03B	53.76B	47.41B	42.20B	37.51B	32.51B	28.68B	24.62B	21.21B	17.84B	15.31B	13.36B	11.78B	10.40B	9.24B	8.29B	7.48B	6.73B	6.05B	5.38B	4.88B	4.28B	3.66B	3.16B
Cost of Revenue	121.13B	112.01B	104.44B	104.44B	95.91B	91.92B	100.75B	89.05B	87.48B	76.59B	54.82B	51.10B	51.29B	51.69B	48.44B	45.72B	42.39B	38.52B	34.24B	30.41B	27.31B	23.71B	21.08B	18.05B	15.24B	12.77B	10.95B	9.52B	8.37B	7.35B	6.50B	5.85B	5.29B	4.74B	4.29B	3.78B	3.41B	2.95B	2.51B	2.16B
Gross Profit	26.52B	27.07B	28.27B	28.07B	26.08B	28.16B	30.79B	29.16B	29.87B	26.86B	21.57B	21.12B	20.34B	20.49B	18.98B	17.61B	16.64B	15.24B	13.17B	11.79B	10.20B	8.80B	7.61B	6.57B	5.97B	5.07B	4.36B	3.85B	3.41B	3.04B	2.74B	2.44B	2.19B	1.99B	1.76B	1.60B	1.47B	1.33B	1.15B	1.00B
Gross Profit Ratio	17.96%	19.46%	21.30%	21.18%	21.38%	23.45%	23.41%	24.67%	25.46%	25.96%	28.23%	29.24%	28.40%	28.39%	28.15%	27.81%	28.19%	28.35%	27.78%	27.93%	27.19%	27.07%	26.52%	26.70%	28.16%	28.42%	28.46%	28.77%	28.96%	29.29%	29.66%	29.42%	29.29%	29.53%	29.13%	29.65%	30.18%	31.16%	31.54%	31.75%
Research & Development	0.00	371.00M	307.00M	284.00M	300.00M	260.00M	254.00M	245.00M	238.00M	178.00M	127.00M	105.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	25.62B	24.70B	24.13B	23.03B	22.30B	22.60B	23.97B	23.05B	22.83B	21.18B	17.43B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	694.00M	775.00M	862.00M	772.00M	532.00M	582.00M	665.00M	571.00M	598.00M	491.00M	265.00M	286.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	28.11B	25.48B	24.99B	23.80B	22.84B	23.18B	24.64B	23.62B	23.43B	21.67B	17.69B	17.47B	16.88B	16.56B	15.52B	14.37B	13.20B	12.09B	10.47B	9.36B	8.06B	6.95B	5.98B	5.18B	4.52B	3.84B	3.33B	2.97B	2.66B	2.39B	2.16B	1.93B	1.74B	1.58B	1.41B	1.28B	1.19B	1.07B	914.00M	791.70M
Other Expenses	0.00	8.10B	1.58B	1.64B	1.96B	-50.00M	-389.00M	-185.00M	210.00M	344.00M	-443.00M	0.00	0.00	-434.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	230.10M	210.10M	189.00M	164.00M	147.30M	131.50M	118.10M	104.70M	92.10M	84.30M	70.40M	63.80M	59.40M	53.70M	43.80M	34.40M
Operating Expenses	40.60B	33.95B	26.88B	25.73B	25.10B	23.39B	24.50B	23.68B	23.87B	22.19B	17.38B	16.98B	16.88B	16.13B	15.52B	14.37B	13.20B	12.09B	10.47B	9.36B	8.06B	6.95B	5.98B	5.18B	4.75B	4.05B	3.52B	3.14B	2.81B	2.52B	2.28B	2.03B	1.83B	1.67B	1.48B	1.34B	1.25B	1.12B	957.80M	826.10M
Cost & Expenses	161.73B	145.96B	131.32B	130.17B	121.00B	115.31B	125.25B	112.73B	111.35B	98.78B	72.20B	68.08B	68.17B	67.82B	63.96B	60.09B	55.59B	50.61B	44.71B	39.78B	35.37B	30.66B	27.06B	23.22B	19.98B	16.82B	14.47B	12.66B	11.17B	9.88B	8.78B	7.89B	7.12B	6.41B	5.76B	5.13B	4.66B	4.07B	3.46B	2.98B
Interest Income	0.00	0.00	0.00	0.00	29.00M	0.00	0.00	0.00	0.00	134.00M	0.00	95.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	482.00M	580.00M	396.00M	491.00M	613.00M	650.00M	616.00M	693.00M	596.00M	605.00M	156.00M	165.00M	88.00M	71.00M	85.00M	83.00M	11.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	2.46B	1.89B	1.68B	1.69B	1.63B	1.78B	1.52B	1.41B	1.48B	1.56B	1.21B	1.18B	1.17B	1.09B	1.03B	975.00M	840.00M	675.90M	572.20M	482.10M	403.10M	346.10M	307.30M	269.20M	230.10M	210.10M	189.00M	164.00M	147.30M	131.50M	118.10M	104.70M	92.10M	84.30M	70.40M	63.80M	59.40M	53.70M	43.80M	34.40M
EBITDA	-11.28B	3.48B	4.96B	5.96B	2.84B	6.75B	7.67B	6.95B	7.93B	6.75B	5.08B	5.34B	4.63B	5.45B	4.49B	4.22B	4.28B	3.83B	3.27B	2.91B	2.55B	2.21B	1.93B	1.67B	1.45B	1.23B	1.02B	872.60M	751.40M	651.60M	573.80M	510.90M	450.60M	405.50M	354.60M	317.30M	283.60M	264.40M	240.40M	212.20M
EBITDA Ratio	-7.64%	-1.86%	4.80%	4.12%	2.37%	5.31%	6.36%	6.09%	6.36%	7.40%	6.58%	7.37%	6.46%	7.55%	6.66%	6.67%	7.25%	7.12%	6.91%	6.89%	6.74%	6.66%	6.71%	6.68%	6.70%	6.87%	6.45%	6.48%	6.34%	6.22%	6.15%	6.16%	5.89%	5.89%	5.61%	5.73%	5.72%	6.15%	6.51%	6.65%
Operating Income	-14.08B	-6.88B	1.39B	2.34B	982.00M	4.77B	6.29B	5.48B	6.00B	4.67B	4.19B	3.65B	3.46B	4.37B	3.46B	3.25B	3.44B	3.15B	2.70B	2.42B	2.14B	1.85B	1.62B	1.40B	1.22B	1.02B	835.00M	708.00M	604.10M	520.10M	455.70M	406.20M	358.50M	321.20M	284.20M	253.50M	224.20M	210.70M	196.60M	177.80M
Operating Income Ratio	-9.53%	-4.95%	1.05%	1.77%	0.81%	3.97%	4.78%	4.64%	5.11%	4.51%	5.49%	5.05%	4.84%	6.05%	5.13%	5.13%	5.83%	5.86%	5.70%	5.74%	5.71%	5.69%	5.66%	5.68%	5.77%	5.69%	5.46%	5.30%	5.13%	5.00%	4.93%	4.90%	4.80%	4.77%	4.70%	4.71%	4.59%	4.92%	5.37%	5.62%
Total Other Income/Expenses	-126.00M	1.46B	2.65B	280.00M	-505.00M	-399.00M	-260.00M	-623.00M	-813.00M	667.00M	-637.00M	-45.00M	-88.00M	-71.00M	-85.00M	-83.00M	-11.00M	28.80M	52.60M	-11.30M	17.00M	23.40M	13.10M	24.40M	39.20M	11.90M	42.10M	4.60M	2.80M	3.70M	2.70M	-6.50M	-5.50M	-9.20M	-3.30M	-9.70M	-15.20M	-16.60M	-9.00M	-4.10M
Income Before Tax	-14.20B	-5.39B	4.04B	2.62B	477.00M	4.37B	6.03B	4.86B	5.19B	5.34B	3.56B	4.05B	3.38B	4.29B	3.37B	3.16B	3.43B	3.19B	2.75B	2.46B	2.18B	1.89B	1.64B	1.42B	1.26B	1.03B	877.00M	712.00M	606.90M	523.80M	458.40M	399.70M	353.00M	312.00M	280.90M	243.80M	209.00M	194.10M	187.60M	173.70M
Income Before Tax Ratio	-9.62%	-3.87%	3.04%	1.98%	0.39%	3.64%	4.58%	4.11%	4.42%	5.16%	4.66%	5.60%	4.71%	5.95%	5.00%	5.00%	5.81%	5.93%	5.81%	5.82%	5.80%	5.81%	5.71%	5.78%	5.96%	5.76%	5.73%	5.33%	5.15%	5.04%	4.96%	4.82%	4.72%	4.63%	4.64%	4.53%	4.28%	4.53%	5.12%	5.49%
Income Tax Expense	1.25B	1.86B	30.00M	667.00M	339.00M	577.00M	998.00M	760.00M	997.00M	1.06B	1.53B	1.50B	1.25B	1.58B	1.28B	1.16B	1.27B	1.15B	1.00B	896.10M	816.10M	713.00M	618.10M	537.10M	486.40M	403.20M	340.00M	276.00M	235.20M	203.00M	176.50M	154.40M	132.40M	117.00M	106.30M	89.60M	79.90M	90.60M	84.50M	79.50M
Net Income	-8.64B	-3.08B	4.34B	2.54B	456.00M	3.98B	5.02B	4.08B	4.17B	4.22B	1.93B	2.55B	2.13B	2.71B	2.09B	2.01B	2.16B	2.04B	1.75B	1.56B	1.36B	1.18B	1.02B	885.60M	776.90M	624.10M	511.00M	436.00M	371.70M	320.80M	281.90M	221.70M	220.60M	195.00M	174.60M	154.20M	129.10M	103.50M	103.10M	94.20M
Net Income Ratio	-5.85%	-2.21%	3.27%	1.92%	0.37%	3.32%	3.82%	3.45%	3.56%	4.08%	2.53%	3.53%	2.97%	3.76%	3.10%	3.17%	3.65%	3.80%	3.69%	3.70%	3.63%	3.62%	3.55%	3.60%	3.66%	3.50%	3.34%	3.26%	3.16%	3.09%	3.05%	2.67%	2.95%	2.90%	2.89%	2.87%	2.64%	2.42%	2.82%	2.98%
EPS	-10.01	-3.57	5.02	2.31	0.20	4.14	5.07	3.80	3.85	4.05	2.03	2.69	2.43	2.97	2.13	2.03	2.18	2.04	1.73	1.53	1.32	1.14	1.00	0.87	0.77	0.62	0.26	0.22	0.38	0.33	0.28	0.03	0.03	0.03	0.01	0.01	0.01	0.01	0.01	0.01
EPS Diluted	-10.01	-3.57	5.01	2.30	0.20	4.13	5.05	3.78	3.82	4.00	2.00	2.67	2.42	2.94	2.12	2.02	2.17	2.03	1.72	1.52	1.31	1.13	0.99	0.86	0.76	0.62	0.26	0.22	0.38	0.33	0.28	0.03	0.03	0.03	0.01	0.01	0.01	0.01	0.01	0.01
Weighted Avg Shares Out	863.10M	863.20M	864.40M	864.80M	879.40M	921.50M	991.00M	1.07B	1.08B	1.04B	953.10M	946.00M	874.70M	915.10M	981.70M	990.00M	990.61M	998.63M	1.01B	1.02B	1.02B	1.02B	1.02B	1.02B	1.01B	1.00B	1.98B	987.58M	991.20M	987.08M	989.12M	984.57M	984.57M	984.57M	984.38M	984.27M	984.22M	984.06M	983.92M	982.37M
Weighted Avg Shares Out (Dil)	863.10M	863.20M	865.90M	866.40M	880.30M	923.50M	995.00M	1.08B	1.09B	1.05B	965.20M	955.20M	880.10M	924.50M	987.90M	991.30M	995.54M	1.01B	1.02B	1.03B	1.03B	1.03B	1.03B	1.03B	1.02B	1.01B	2.01B	987.58M	991.20M	987.08M	989.12M	984.57M	984.57M	984.57M	984.38M	984.27M	984.22M	984.06M	983.92M	982.37M

Walgreens Boots Alliance Schedules Fiscal 2025 First Quarter Earnings Announcement for January 9

December 6, 2024businesswire.com

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) will release its fiscal year 2025 first quarter results at 7 a.m. ET on Thursday, January 9, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET. The...

WBA Class Action Alert: Robbins LLP Reminds Warner Bros. Discovery, Inc. Investors of the Lead Plaintiff Deadline in the Pending WBA Securities Class Action

December 5, 2024accesswire.com

SAN DIEGO, CA / ACCESSWIRE / December 5, 2024 / Robbins LLP reminds investors that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Warner Bros. Discovery, Inc. (NASDAQ:WBD) securities between February 23,...

Is Now the Time to Buy 3 of the S&P 500's Worst-Performing Stocks of 2024?

December 5, 2024fool.com

The S&P 500 has hit record levels this year and many stocks have generated fantastic returns for investors. But there's been no shortage of struggling investments, either.

These 2 Retail and Wholesale Stocks Could Beat Earnings: Why They Should Be on Your Radar

December 3, 2024zacks.com

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Walgreens Boots Alliance Provides Notice of Pending and Proposed Settlement of Shareholder Derivative Action

November 29, 2024businesswire.com

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots (NASDAQ:WBA): IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE JAMES CLEM, Derivatively on Behalf of WALGREENS BOOTS ALLIANCE, INC., Plaintiff, v. JAMES A. SKINNER, STEFANO PESSINA, WILLIAM C. FOOTE, NANCY M....

Pharma-Grade Cannabis Could Hit Walgreens & CVS—But Can The Industry Survive The FDA?

November 28, 2024benzinga.com

As the formal review process for rescheduling cannabis unfolds, industry players are closely watching its potential to transform the sector. With the DEA hearing delayed until early 2025 and a possible Trump presidency adding uncertainty, cannabis businesses are preparing for...

Should You Buy the 3 Highest-Paying Dividend Stocks in the S&P 500?

November 26, 2024fool.com

The power of owning dividend-paying stocks is often underappreciated. Consider, for example, that a study by Hartford Funds and Ned Davis Research found that between 1973 and 2023, companies that grew or initiated dividend payments delivered annualized returns of 10.2%,...

Billionaire Israel Englander Sold 70% of Millennium's Stake in Nvidia and Is Piling Into a Supercharged Dividend Stock With a Nearly 12% Yield

November 26, 2024fool.com

Less than two weeks ago, Wall Street and investors were privy to one of the most important data releases of the fourth quarter -- and no, I'm not talking about the October inflation report.